{
    "nctId": "NCT00608972",
    "briefTitle": "Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer",
    "officialTitle": "A Phase II Trial of Doxil, Carboplatin and Bevacizumab in Triple Negative Previously Untreated Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 31,
    "primaryOutcomeMeasure": "Progression Free Survival (PFS) After Treatment With Doxil, Carboplatin and Bevacizumab in Patients With ER, PR, HER2neu Negative Metastatic Breast Cancer",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Women with previously untreated metastatic breast cancer, ER/PR/HER2/neu negative.\n2. Age \\>= 18\n3. ECOG performance status \\<= 2\n4. Normal organ and marrow function\n5. Normal cardiac function as evidenced by LVEF within institutional normal limits\n\nExclusion Criteria:\n\n1. History of hypersensitivity reactions to doxil or bevacizumab\n2. Myocardial infarct or unstable angina within 6 months before enrollment\n3. Prior anthracycline dose exceeding 360 mg/m2 for doxorubicin (including DOXIL) or 720 mg/m2 for epirubicin.\n4. Proteinuria",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}